$Tempus AI(TEM)$ CFO said on a call that Ambry today doesn't have a data business so right away tem will be able to monetize that data once they are able to integrate and de-identify it. Believe Ambry was the biggest hereditary cancer screening company. So if that data is deemed valuable by pharmaceuticals and other medical companies, this could be a gold mine that Tempus got for super cheap.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

  • Top
  • Latest
empty
No comments yet